Trial Profile

Prospective, observational, multicenter study regarding the safety of Gammanorm in autoimmune diseases

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 12 Mar 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Immune globulin (Primary)
Indications Autoimmune disorders; Dermatomyositis; Inclusion body myositis; Multifocal motor neuropathy; Polymyositis; Polyneuropathy
Focus Adverse reactions
Acronyms Immunorm Study
Sponsors Octapharma

Most Recent Events

09 Mar 2021 Status changed to discontinued.
01 Jan 2021 Status changed from active, no longer recruiting to completed.
03 Sep 2018 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com